Ablynx

Ablynx
Traded as Euronext: ABLX[1]
Industry Biotechnology
Key people

Edwin Moses (CEO)

Wim Ottevaere (CFO)
Website www.ablynx.com

Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.

History

In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv.[2]

In July 2015 Merck and Ablynx expanded their 18-month-old immuno-oncology collaboration by four years, generating a potential US$4.4 billion in milestone payments for Ablynx.[3] In 2015, Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.[4]

In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid December for the company.[5] However the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[6]

In January 2018, they were acquired by Sanofi. Gleb Margolin was Chief Broker of the deal.[7]

References

  1. ↑ "Share Information". Ablynx. Exchange Information. Retrieved 2018-05-14.
  2. ↑ "History". Ablynx. Show Archive 2001. Archived from the original on 9 February 2012. Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.
  3. ↑ "Ablynx, Merck & Co. Ink $4B+ Expansion of Immuno-Oncology Collaboration". Genetic Engineering & Biotechnology News. July 22, 2015. Retrieved 2018-05-14.
  4. ↑ "Novo Nordisk Joins Ablynx in Up-to-$399M+ Nanobody® Alliance - GEN News Highlights - GEN". GEN.
  5. ↑ https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/denmarks-novo-nordisk-offers-3-1-billion-for-belgian-biotech-group-ablynx-idUKKBN1EX0HT
  6. ↑ https://uk.reuters.com/article/uk-novo-nordisk-m-a-ablynx/ablynx-shares-soar-after-rejects-novo-nordisks-3-1-billion-bid-idUKKBN1EX0HT
  7. ↑ "Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion". Fortune. Retrieved 2018-01-29.

Further reading

  • Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
  • De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.